INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,493,000 | -58.6% | 32,071 | -49.3% | 0.01% | -65.7% |
| Q2 2022 | $3,608,000 | -39.8% | 63,201 | -35.5% | 0.04% | -35.2% |
| Q1 2022 | $5,992,000 | +427.0% | 97,925 | +351.0% | 0.05% | +440.0% |
| Q4 2021 | $1,137,000 | -45.4% | 21,715 | -83.5% | 0.01% | -94.7% |
| Q3 2017 | $2,083,000 | +313.3% | 131,980 | +325.9% | 0.19% | +272.5% |
| Q1 2017 | $504,000 | +9.6% | 30,989 | +161.0% | 0.05% | -50.5% |
| Q2 2016 | $460,000 | – | 11,871 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |